NBP NASDAQ
NovaBridge Biosciences
1W: -1.4%
1M: -24.0%
3M: -32.3%
YTD: -68.2%
1Y: -64.8%
3Y: +10.6%
5Y: -98.0%
$1.35
+0.01 (+1.12%)
Weekly Expected Move ±5.6%
$1
$1
$1
$1
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$0
-100.0% ▼
Gross Profit
$0
-100.0% ▼
Operating Income
-$375M
+26.6% ▲
Net Income
-$162M
+88.9% ▲
EPS (Diluted)
$-4.46
+74.7% ▲
EBITDA
-$373M
-8.5% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $1.5B | $88M | -$11M | $4M | $0 |
| YoY Growth | +5042.2% | -94.3% | -112.2% | +141.9% | -100.0% |
| Cost of Revenue | $0 | $46M | $27M | $0 | $0 |
| Gross Profit | $1.5B | $42M | -$249M | $4M | $0 |
| Gross Margin | 100.0% | 47.3% | 2325.8% | 100.0% | — |
| R&D Expenses | $985M | $190M | $156M | $114M | $159M |
| SG&A Expenses | $402M | $900M | $200M | $64M | $216M |
| Operating Expenses | $1.4B | $2.1B | $355M | $516M | $375M |
| Operating Income | $156M | -$2.1B | -$366M | -$511M | -$375M |
| Operating Margin | 10.1% | -2353.1% | 3422.2% | -11395.1% | — |
| Interest Expense | $146K | $0 | $0 | $102K | $0 |
| Income Before Tax | $483M | -$2.3B | -$973M | -$1.5B | -$363M |
| Tax Expense | $12M | -$495K | $697K | -$1.3B | $0 |
| Net Income | $471M | -$2.3B | -$2.5B | -$1.5B | -$162M |
| Net Margin | 30.5% | -2648.7% | 23438.9% | -32674.0% | — |
| EPS (Diluted) | $6.90 | $-30.68 | $-30.38 | $-17.62 | $-4.46 |
| EBITDA | $168M | -$2.1B | -$51M | -$344M | -$373M |
| Shares Outstanding | 68M | 76M | 83M | 83M | 81M |